Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?

López C, Yepes-Pérez Y, Hincapié-Escobar N, Díaz-Arévalo D, Patarroyo MA.

Front Immunol. 2017 Feb 13;8:126. doi: 10.3389/fimmu.2017.00126. Review.

2.

Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.

Radtke AJ, Anderson CF, Riteau N, Rausch K, Scaria P, Kelnhofer ER, Howard RF, Sher A, Germain RN, Duffy P.

Sci Rep. 2017 Jan 16;7:40312. doi: 10.1038/srep40312.

3.

Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35.

Kalra A, Edula JR, Gupta PK, Pandey AK, Chauhan VS.

PLoS One. 2016 Oct 31;11(10):e0165720. doi: 10.1371/journal.pone.0165720.

4.

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.

Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, Rausch KM, Zhu D, Muratova O, Herrera R, Anderson C, Jones D, Aebig J, Brockley S, MacDonald NJ, Wang X, Fay MP, Healy SA, Durbin AP, Narum DL, Wu Y, Duffy PE.

PLoS One. 2016 Oct 17;11(10):e0163144. doi: 10.1371/journal.pone.0163144.

5.

Strategies & recent development of transmission-blocking vaccines against Plasmodium falciparum.

Chaturvedi N, Bharti PK, Tiwari A, Singh N.

Indian J Med Res. 2016 Jun;143(6):696-711. doi: 10.4103/0971-5916.191927. Review.

6.

An inter-laboratory comparison of standard membrane-feeding assays for evaluation of malaria transmission-blocking vaccines.

Miura K, Stone WJ, Koolen KM, Deng B, Zhou L, van Gemert GJ, Locke E, Morin M, Bousema T, Sauerwein RW, Long CA, Dechering KJ.

Malar J. 2016 Sep 9;15:463. doi: 10.1186/s12936-016-1515-z.

7.

Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.

Lee SM, Wu CK, Plieskatt J, McAdams DH, Miura K, Ockenhouse C, King CR.

Malar J. 2016 Aug 11;15(1):405. doi: 10.1186/s12936-016-1464-6.

8.

Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii.

Zheng L, Pang W, Qi Z, Luo E, Cui L, Cao Y.

Parasit Vectors. 2016 Aug 8;9(1):433. doi: 10.1186/s13071-016-1711-2.

9.

Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.

MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera R, Burkhardt M, Muratova O, Kumar K, Aebig J, Rausch K, Lambert L, Dawson N, Sattabongkot J, Ambroggio X, Duffy PE, Wu Y, Narum DL.

J Biol Chem. 2016 Sep 16;291(38):19913-22. doi: 10.1074/jbc.M116.732305.

PMID:
27432885
10.

Optimization of a Membrane Feeding Assay for Plasmodium vivax Infection in Anopheles albimanus.

Vallejo AF, Rubiano K, Amado A, Krystosik AR, Herrera S, Arévalo-Herrera M.

PLoS Negl Trop Dis. 2016 Jun 29;10(6):e0004807. doi: 10.1371/journal.pntd.0004807.

11.

Plasmodium falciparum gametocyte transit through the cutaneous microvasculature: A new target for malaria transmission blocking vaccines?

Nixon CP.

Hum Vaccin Immunother. 2016 Dec;12(12):3189-3195. doi: 10.1080/21645515.2016.1183076.

PMID:
27184760
12.

Bacterial superglue enables easy development of efficient virus-like particle based vaccines.

Thrane S, Janitzek CM, Matondo S, Resende M, Gustavsson T, de Jongh WA, Clemmensen S, Roeffen W, van de Vegte-Bolmer M, van Gemert GJ, Sauerwein R, Schiller JT, Nielsen MA, Theander TG, Salanti A, Sander AF.

J Nanobiotechnology. 2016 Apr 27;14:30. doi: 10.1186/s12951-016-0181-1.

13.

Identification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium berghei.

Zheng W, Kou X, Du Y, Liu F, Yu C, Tsuboi T, Fan Q, Luo E, Cao Y, Cui L.

Vaccine. 2016 May 17;34(23):2570-8. doi: 10.1016/j.vaccine.2016.04.011.

PMID:
27083421
14.

Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine.

Kou X, Zheng W, Du F, Liu F, Wang M, Fan Q, Cui L, Luo E, Cao Y.

Parasit Vectors. 2016 Apr 2;9:190. doi: 10.1186/s13071-016-1459-8. Erratum in: Parasit Vectors. 2017 Feb 16;10 (1):84.

15.

Antibody Profiling in Naïve and Semi-immune Individuals Experimentally Challenged with Plasmodium vivax Sporozoites.

Arévalo-Herrera M, Lopez-Perez M, Dotsey E, Jain A, Rubiano K, Felgner PL, Davies DH, Herrera S.

PLoS Negl Trop Dis. 2016 Mar 25;10(3):e0004563. doi: 10.1371/journal.pntd.0004563.

16.

Transmission-blocking strategies: the roadmap from laboratory bench to the community.

Gonçalves D, Hunziker P.

Malar J. 2016 Feb 18;15:95. doi: 10.1186/s12936-016-1163-3. Review.

17.

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.

Li Y, Leneghan DB, Miura K, Nikolaeva D, Brian IJ, Dicks MD, Fyfe AJ, Zakutansky SE, de Cassan S, Long CA, Draper SJ, Hill AV, Hill F, Biswas S.

Sci Rep. 2016 Jan 8;6:18848. doi: 10.1038/srep18848.

18.

A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.

Hostetler JB, Sharma S, Bartholdson SJ, Wright GJ, Fairhurst RM, Rayner JC.

PLoS Negl Trop Dis. 2015 Dec 23;9(12):e0004264. doi: 10.1371/journal.pntd.0004264.

19.

Tailoring a Combination Preerythrocytic Malaria Vaccine.

Bauza K, Atcheson E, Malinauskas T, Blagborough AM, Reyes-Sandoval A.

Infect Immun. 2015 Dec 14;84(3):622-34. doi: 10.1128/IAI.01063-15.

20.

Plant expression and characterization of the transmission-blocking vaccine candidate PfGAP50.

Beiss V, Spiegel H, Boes A, Scheuermayer M, Reimann A, Schillberg S, Fischer R.

BMC Biotechnol. 2015 Dec 1;15:108. doi: 10.1186/s12896-015-0225-x.

Supplemental Content

Support Center